An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of Strength in Patients With Pancreatic or Stomach Cancer Receiving Chemoradiation Therapy Before Surgery, SurgeryStrong Study
NCT ID: NCT05056805
Last Updated: 2024-10-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2021-03-04
2022-09-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developing Prehabilitation Program in Patients With Operable Pancreatic Cancer Perioperatively and Following Surgery
NCT02900677
A Pilot Study of the Effect of High Protein Supplement and Exercise Therapy on Preservation of Skeletal Muscle Mass and Quality of Life in Patients With Gastric Cancer and Pancreatic Cancer Treated With Chemotherapy
NCT05573776
Preoperative Exercise in Pancreatic Cancer
NCT02648880
STRONG Program for Cancer Patients
NCT05649969
Exercise Regimens and Neoadjuvant Chemotherapy
NCT04685759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. In patients with pancreatic and gastric cancer undergoing preoperative chemoradiation and potentially curative resection, compare the change in dynamic lower muscle strength as measured by the 1 repetition maximum (1-RM) leg press between the time of enrollment and prior to resection in those who: a. Are offered aerobic exercise encouragement prior to surgery b. Are offered aerobic exercise encouragement, nutrition monitoring, and a structured strength exercise program prior to surgery.
SECONDARY OBJECTIVES:
I. To compare the change in dynamic muscle strength as measured by the 1-RM for the chest press, seated row, and leg extension.
II. To compare upper and lower body muscle endurance as defined by the maximal number of repetitions performed at 70% of the pre-exercise 1-RM for the chest and leg press.
III. To compare the change in the six minute walk test (6MWT) distance of patients between the time of enrollment and prior to resection.
IV. To compare physical function (patient-reported based on the Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function Short Form and objectively based on grip strength) between groups.
V. To compare the quality of life (Functional Assessment of Cancer Therapy, patients with hepatobiliary cancer \[FACT-Hep\]) between groups.
VI. To compare exercise motivation (Behavioral Regulation in Exercise Questionnaire \[BREQ\]-3) between groups.
VII. To compare anthropometric measures (e.g., weight, skeletal muscle, visceral fat and subcutaneous fat) using SliceOMatic software from usual care computed tomography (CT) scans between groups.
VIII. To assess the incidence of perioperative adverse events that occur within 90 days between groups (Accordion score).
IX. To compare changes in physical activity between the time of enrollment and immediately prior to surgery based on the Modified Godin-Shephard Leisure Time Physical Activity Questionnaire.
X. To evaluate feasibility of patient completion of 24-hour recall via Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA-24).
XI. To measure adoption of nutrition recommendations as compared to baseline. XII. To compare adherence to nutrition recommendations within and between groups.
XIII. To compare "usual care" laboratory studies including those that are indicators of nutritional status within and between groups.
XIV. To compare the vascular and tumor structure, and immune cell infiltration in tumors between patients in different groups.
XV. To compare potential biomarkers of angiogenesis and inflammation that correlate with exercise, disease pathology, and/or clinical and functional outcomes.
XVI. To store in a research bank any remaining tissue or blood (collected for the purposes of the above objectives) for the possibility of future analysis.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients are encouraged to complete at least 30 minutes of moderate intensity aerobic exercise, at least 3 times per week. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Aerobic exercises and nutrition are tracked in the Pt Pal app.
ARM B: Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
After randomization, patients are followed up at 4-6 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A (aerobic exercise, nutritional recommendation)
Patients are encouraged to complete at least 30 minutes of moderate intensity aerobic exercise, at least 3 times per week. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Aerobic exercises and nutrition are tracked in the Pt Pal app
Aerobic Exercise
Receive aerobic exercise encouragement
Nutritional Intervention
Receive nutritional consultation and guidelines
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Arm B (aerobic, strength exercise, nutritional recommendation)
Patients complete at least 30 minutes of moderate intensity aerobic exercise (such as brisk walking or stationary bike cycling) at least 3 times per week. Patients also complete strength exercises with resistance tubes/bands at least 2 times per week, with at least 2 sets of 8-15 repetitions of the exercises taught. Patients receive nutrition consultation with a registered dietitian and monitor dietary intake. Patients also consume a high protein snack/meal/shake (15-25 grams) within 1 hour after any strengthening exercises. Exercise activities and nutrition are tracked in the Pt Pal app.
Aerobic Exercise
Receive aerobic exercise encouragement
Dietary Intervention
Consume high protein snack/meal/shake
Nutritional Intervention
Receive nutritional consultation and guidelines
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Resistance Training
Complete strengthening exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aerobic Exercise
Receive aerobic exercise encouragement
Dietary Intervention
Consume high protein snack/meal/shake
Nutritional Intervention
Receive nutritional consultation and guidelines
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Resistance Training
Complete strengthening exercise
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have completed or are within 2 weeks of completion of preoperative chemoradiotherapy either on- or off-protocol
* Anticipated to undergo potentially curative resection in 4-6 weeks from enrollment
* Able to understand the description of the study and willing to participate
* Able to understand the exercise program
* Able to independently maintain daily exercise logs via Pt Pal -iOS, Android or desktop web browser on their own personal device
* Telephone or email access and agreement to engage with the research personnel via phone or email
* Meet all screening requirements, including physician clearance
* \>= age 18
Exclusion Criteria
* Has participated in moderate to high intensity strengthening exercises at least two times per week within the past four weeks prior to enrollment
* Unable to complete the baseline assessment questionnaires or functional assessments
* Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV)
* Recent fracture or acute musculoskeletal injury that precludes the ability to weight bear fully on all 4 limbs in order to participate in an exercise intervention
* Numeric pain rating scale of \>= 7 out of 10
* Myopathic or rheumatologic disease that impacts physical function
* Recurrent cancer following prior resection
* \< age 18
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew H Katz
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2021-02655
Identifier Type: REGISTRY
Identifier Source: secondary_id
2020-0026
Identifier Type: OTHER
Identifier Source: secondary_id
2020-0026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.